Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Primary Objectives:

--Compare the humoral responses in terms of difference in IgG titers at 1 month from routine single dose PCV20 or a boosted PCV20 regimen in B cell lymphoma survivors who previously received treatment with anti-CD20 therapy.

Secondary Objectives:

• Compare the humoral responses in terms of difference in IgG titers at 3, 6 and12 from routine single dose PCV20 or a boosted PCV20 regimen in B cell lymphoma survivors who previously received treatment with anti-CD20 therapy.
• Estimate the rate of pneumonia (all bacterial pneumonia including pneumococcal pneumonia) within a year from routine single dose PCV20 or a boosted PCV20 regimen in lymphoma survivors who previously received treatment with anti-CD 20 therapy.
• Correlate humoral responses to development of bacterial pneumonia and pneumococcal pneumonia and with severity of this infection in lymphoma survivors within a year of vaccination.

Inclusion criteria

• Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.
• Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.
• Patients who are at least 18 years of age.
• Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.

Exclusion criteria

• Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.
• Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.
• Patients who are unable to attend follow-up appointments at designated times at MD Anderson.
• Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)